The results of the third batch of national selection will be announced, and the pharmaceutical market will be reshuffled.

"Pharmaceutical network industry dynamics" the second batch of national mining on the industry's impact on the after-effects of the undefined, only 7 months later, nearly 200 pharmaceutical companies related to the person in charge of yesterday re-gathered in Shanghai, began the third batch of national 56 product regulations of the quotation.
, the Joint Procurement Office has been the national centralized procurement of drugs (procurement document number: GY-YD2020-1) to be selected results for publicity.
according to the results, the price killing of various pharmaceutical companies is extremely fierce.
a total of 189 enterprises participated in the procurement, resulting in 125 enterprises to be selected, 191 products to be selected, 55 varieties of drugs to be won, the average price reduction of the products to be selected 53%.
It is worth noting that in the first batch of national mining, Bayer Akapo sugar with a huge price reduction of 90% became the point of the time, and this time, the main character was replaced by Qilu Pharmaceuticals, in the competition foracid sidina non-tablets, Qilu Pharmaceuticals with a successful bid of 2.082 yuan per tablet, causing a surprise in the industry.
In addition, there are a number of enterprises fell by more than 90%, according to incomplete statistics, to be included in 56 varieties of at least 14 "one cent" varieties, of which Chongqing Core Pharmaceuticals fell by 92%, the "God medicine" metformin (250mg) prices to 1 minute 5 pieces.
As can be seen from the above, low prices are still the main theme of volume procurement, but the enterprise quotation strategy has become mature, there are enterprises willing to low prices to grab the volume of the market, there are enterprises to abandon the bid to grab the surplus market.
Such as generic pharmaceutical companies, although fierce competition, but many of the original pharmaceutical companies GSK, Mercerton, Roche, Lilly and other direct abandonment of the bid, only Weishi, Pfizer and Youshibi three original research products to be selected.
actually, in any case, in this wave of mass procurement, the impact of the larger or pharmaceutical representatives and other practitioners, there are many pharmaceutical representatives said that whether their products are not included, or will be laid off.
, there are also industry insiders said that the next pharmaceutical industry may usher in a wave of "departure tide."
how many people will make a big change in their careers after this national harvest is not yet known.
, however, it is worth noting that according to the data, the total sales of 56 varieties in China's public medical institutions in 2019 exceeded 54 billion yuan.
according to the 56 procurement varieties in the first year agreed procurement volume and the 6th effective declaration price, the third batch of collection and mining involved in the 1st agreed procurement amount of about 22.64 billion yuan.
From the procurement amount and constantly covering the products and bidding enterprises continue to increase, whether it is generic drugs companies or original pharmaceutical companies, the future will have to face the situation of normal procurement with volume, leaving little room for enterprises to move.
industry believes that in the next two years, the domestic drug market will usher in a major reshuffle.
the National Health Insurance Administration, will be implemented under the principle of "all necessary", pharmaceutical companies need to actively expand other drug sales channels.
.